<DOC>
	<DOCNO>NCT01567930</DOCNO>
	<brief_summary>The purpose study evaluate activity temsirolimus patient advance hepatocellular carcinoma ( HCC ) treat one previous chemotherapy biologic therapy like sorafenib , experience disease progression intolerance therapy .</brief_summary>
	<brief_title>Temsirolimus Second-line Therapy HCC</brief_title>
	<detailed_description>Currently , standard therapy exist patient progress sorafenib . mTOR signal often up-regulated HCC promote cell growth survival . This process inhibit rapamycin , specific inhibitor mTOR . Temsirolimus , rapamycin analog , may delay tumor progression inhibit mTOR HCC.Intervention : Temsirolimus IV Eligible patient receive temsirolimus IV day 1,8,15 every 21 day . Treatment continue till disease progression untolerable side effect</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients must advance unresectable metastatic hepatocellular carcinoma ( HCC ) . Prior diagnosis HCC could establish histologically base one follow criterion : Liver mass &gt; 2cm : Characteristic enhancement least one imaging technique ( triphasic CT scan , MRI , contrast enhance ultrasound ) AFP &gt; 200 ng/ml . Liver mass 1 2 cm : Characteristic enhancement two image techniques.Diagnosis HCC must confirm biopsy noncharacteristic enhancement imaging . 2 . All patient must receive exactly one prior systemic therapy ( cytotoxic chemotherapy target therapy ) must eligible locoregional treatment modality . 3 . All patient must measurable disease per RECIST criterion . 4 . Patients previous locoregional therapy , include limited radiofrequency ablation , cryoablation , percutaneous ethanol injection , chemoembolization , hepatic artery embolization , hepatic artery infuse FUDR , stereotactic radiotherapy eligible provide documented progression disease measurable extrahepatic disease . 5 . Patients must ECOG performance status 0 2 ( see Appendix B ) . 6 . Patients must great equal 18 year age . 7 . Patients ChildPugh class A ( score 56 ) class B ( score 79 ) eligible . 8 . Patients must adequate organ function define : AST , ALT Alkaline phosphatase ≤ 5x upper limit normal ( ULN ) Total Bilirubin &lt; 2 mg/dl . Creatinine clearance ≥ 15ml/min &amp; patient must dialysis dependent . 9 . Patients must adequate bone marrow function define : Leukocytes ≥ 2000 / mm3 absolute neutrophil count ( ANC ) ≥ 1000 / mm3 Platelet count ≥ 75000 / mm3 10 . Pregnant nursing woman exclude study . All patient reproductive potential must agree use adequate birth control measure eligible study enrollment . 11 . Prior palliative radiotherapy permissible provide complete least 2 week prior study entry patient recover radiationrelated side effect . 12 . Patients must receive investigational agent anticancer therapy . At least 28 day must elapse since completion previous systemic therapy prior study entry patient recover toxicity relate prior therapy . 13 . Patients must history malignancy active require therapy ( nonmelanoma skin cancer ) . 1 . Patients prior treatment mTOR inhibitor eligible . 2 . Patients history uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement eligible . 3 . Patients take cytochrome P450 enzymeinducers inhibitor eligible . 4 . Patients known history HIV infection eligible . 5 . Patients uncontrolled hyperlipidemia hypercholesterolemia eligible ( fast serum cholesterol &gt; 350 mg/dL fast serum triglyceride &gt; 400 mg/dL ) . 6 . Patients known history clinical evidence CNS metastases eligible . 7 . Patients , best judgment investigator , able comply requirement protocol eligible . 8 . Patients ChildPugh class C liver disease eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Temsirolimus</keyword>
	<keyword>HCC</keyword>
	<keyword>Advanced hepatocellular carcinoma</keyword>
</DOC>